• Keros Therapeutics director Anne Prener filed an initial Form 3 on July 6, 2026 following a July 1, 2026 reporting event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001797917-26-000005), on July 06, 2026, and is solely responsible for the information contained therein.